Value
4.5/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 7.5 |
GLUE · Why this verdict
Why Monte Rosa Therapeutics (GLUE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts collectively project roughly 78% upside from current levels, with the stock approximately 55% below their consensus target — a gap that reflects the option value embedded in the drug pipeline even as the business itself burns cash. Sentiment breakdown | At least one clinical or regulatory milestone is achieved within 12 months that causes analysts to maintain or raise their price targets, keeping the 55.2% upside thesis intact. | →Stable |
| CounterAnalyst price targets for clinical-stage biotechs embed probability-weighted pipeline values that can deflate entirely on a single negative trial readout; one disappointing clinical result could cause consensus estimate cuts that eliminate the stated upside. | ||
Free cash flow is deeply negative at 180% of revenue, the Piotroski F-Score is 2 out of 9, and no identifiable competitive moat exists — a combination that produces a quality score of 1.4 and produces a SELL output signal from the position. Quality breakdown | Free cash flow losses narrow to less than 80% of quarterly revenue for 2 consecutive quarters and the Piotroski score improves to at least 5, signaling the business is approaching an inflection toward financial stability. | →Stable |
| CounterClinical-stage biotechs routinely run deeply cash-negative relative to revenue; the 55.2% analyst upside implies the market is pricing anticipated pipeline success rather than current earnings quality, and a quality score may be an inadequate lens for this stage of development. | ||
The two most recent quarters both missed estimates — by 19% and 63% respectively — reversing two earlier beats; this deterioration in execution relative to expectations compounds the fundamental quality concern. Earnings | EPS surprises return to positive territory for 2 consecutive quarters, reversing the recent miss pattern and indicating guidance reliability has improved. | →Stable |
| CounterThe two older quarters in the record beat estimates by 6% and 60%, demonstrating the company can outperform when operational conditions align; recent misses may reflect timing of R&D expenditures rather than a structural deterioration in the development program. | ||
Short interest stands at 19% with a put/call ratio of 2.00 — meaning two put contracts are outstanding for every call — indicating the market's most active participants are positioned for downside, a bearish weight that adds to the fundamental risks. Risk breakdown | Short interest falls below 10% for 2 consecutive months and the put/call ratio compresses below 1.0, signaling meaningful unwinding of the bearish positioning. | →Stable |
| CounterHigh short interest can create a short-squeeze dynamic that propels the stock sharply higher if a positive clinical catalyst forces rapid covering, temporarily turning a bearish positioning signal into a near-term upside accelerant. | ||
Analysts collectively project roughly 78% upside from current levels, with the stock approximately 55% below their consensus target — a gap that reflects the option value embedded in the drug pipeline even as the business itself burns cash.
→StableSentiment breakdown
- Expectation
- At least one clinical or regulatory milestone is achieved within 12 months that causes analysts to maintain or raise their price targets, keeping the 55.2% upside thesis intact.
CounterAnalyst price targets for clinical-stage biotechs embed probability-weighted pipeline values that can deflate entirely on a single negative trial readout; one disappointing clinical result could cause consensus estimate cuts that eliminate the stated upside.
Free cash flow is deeply negative at 180% of revenue, the Piotroski F-Score is 2 out of 9, and no identifiable competitive moat exists — a combination that produces a quality score of 1.4 and produces a SELL output signal from the position.
→StableQuality breakdown
- Expectation
- Free cash flow losses narrow to less than 80% of quarterly revenue for 2 consecutive quarters and the Piotroski score improves to at least 5, signaling the business is approaching an inflection toward financial stability.
CounterClinical-stage biotechs routinely run deeply cash-negative relative to revenue; the 55.2% analyst upside implies the market is pricing anticipated pipeline success rather than current earnings quality, and a quality score may be an inadequate lens for this stage of development.
The two most recent quarters both missed estimates — by 19% and 63% respectively — reversing two earlier beats; this deterioration in execution relative to expectations compounds the fundamental quality concern.
→StableEarnings
- Expectation
- EPS surprises return to positive territory for 2 consecutive quarters, reversing the recent miss pattern and indicating guidance reliability has improved.
CounterThe two older quarters in the record beat estimates by 6% and 60%, demonstrating the company can outperform when operational conditions align; recent misses may reflect timing of R&D expenditures rather than a structural deterioration in the development program.
Short interest stands at 19% with a put/call ratio of 2.00 — meaning two put contracts are outstanding for every call — indicating the market's most active participants are positioned for downside, a bearish weight that adds to the fundamental risks.
→StableRisk breakdown
- Expectation
- Short interest falls below 10% for 2 consecutive months and the put/call ratio compresses below 1.0, signaling meaningful unwinding of the bearish positioning.
CounterHigh short interest can create a short-squeeze dynamic that propels the stock sharply higher if a positive clinical catalyst forces rapid covering, temporarily turning a bearish positioning signal into a near-term upside accelerant.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Monte Rosa Therapeutics carries roughly 55% theoretical upside to analyst consensus with meaningful institutional interest, but a quality score of 1.4, free cash flow burning at 180% of revenue, and two consecutive earnings misses make this an unsuitable position at minimum quality standards — the wide upside reflects pipeline optionality, not current business strength.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 2.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -180% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.6 |
- ▸Overbought (RSI 80)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.0 |
| Analyst rating | 7.6 |
| Price target | 9.3 |
- ▸LLM news sentiment: +0.40 (n=1)
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 43%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $1,824,105 (0.089% of mkt cap)
Peer rank
1.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.0 |
| quality rank | 5.3 |
| growth rank | 0.2 |
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.1 |
| support resistance | 2.2 |
| 52w position | 8.0 |
Risk (lower is worse)
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.4 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 4.8 |
| debt equity | 0.0 |
- ▸High short interest justified: 21%
- ▸High IV: 140%
- ▸Above max pain $2
Catalyst
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.5 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.7>=5.5
- ASYMMETRY:1.6>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.40
- EARNINGS_PROXIMITY:31d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
1.61
Upside
+24.1%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.9 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 7.9, Momentum at 6.7, and Growth at 5.0; the weakest are Quality at 1.4, Peer rank at 1.8, and Risk (lower is worse) at 2.4. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 1.61 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burn Quality Floor Breach
Trip ifFree cash flow loss narrows to less than 80% of quarterly revenue for 2 consecutive quarters, showing meaningful cash burn improvement.
- P2Recent Earnings Miss Trend
Trip ifEPS surprise exceeds 0% for 2 consecutive quarters, reversing the current miss trend.
- P3High Short Interest Bear Positioning
Trip ifShort interest falls below 10% for 2 consecutive months.
- P4Analyst Upside Pipeline Optionality
Trip ifAnalyst consensus price target is cut by more than 30% from current levels, reducing stated upside to less than 25%.